Karyopharm Therapeutics Statistics
Share Statistics
Karyopharm Therapeutics has 126.19M shares outstanding. The number of shares has increased by 8.86% in one year.
| Shares Outstanding | 126.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.05% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 115.36M |
| Failed to Deliver (FTD) Shares | 902 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 17.69M, so 14.12% of the outstanding shares have been sold short.
| Short Interest | 17.69M |
| Short % of Shares Out | 14.12% |
| Short % of Float | 15.43% |
| Short Ratio (days to cover) | 18.28 |
Valuation Ratios
The PE ratio is -0.69 and the forward PE ratio is -1.26.
| PE Ratio | -0.69 |
| Forward PE | -1.26 |
| PS Ratio | 0.68 |
| Forward PS | 0.5 |
| PB Ratio | -0.73 |
| P/FCF Ratio | -1.07 |
| PEG Ratio | n/a |
Enterprise Valuation
Karyopharm Therapeutics Inc. has an Enterprise Value (EV) of 222.93M.
| EV / Earnings | -1.56 |
| EV / Sales | 1.53 |
| EV / EBITDA | -1.88 |
| EV / EBIT | -1.72 |
| EV / FCF | -2.4 |
Financial Position
The company has a current ratio of 3.37, with a Debt / Equity ratio of -1.28.
| Current Ratio | 3.37 |
| Quick Ratio | 3.32 |
| Debt / Equity | -1.28 |
| Total Debt / Capitalization | 458.24 |
| Cash Flow / Debt | -0.53 |
| Interest Coverage | -5.44 |
Financial Efficiency
Return on equity (ROE) is 1.05% and return on capital (ROIC) is -318.14%.
| Return on Equity (ROE) | 1.05% |
| Return on Assets (ROA) | -0.6% |
| Return on Capital (ROIC) | -318.14% |
| Revenue Per Employee | 449.33K |
| Profits Per Employee | -440.30K |
| Employee Count | 325 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.62 |
Taxes
| Income Tax | 323.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -9.67% in the last 52 weeks. The beta is 0.15, so Karyopharm Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.15 |
| 52-Week Price Change | -9.67% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 32.1 |
| Average Volume (20 Days) | 855.80K |
Income Statement
In the last 12 months, Karyopharm Therapeutics had revenue of $146.03M and earned -$143.10M in profits. Earnings per share was $-1.25.
| Revenue | 146.03M |
| Gross Profit | 141.09M |
| Operating Income | -129.54M |
| Net Income | -143.10M |
| EBITDA | -118.42M |
| EBIT | -129.54M |
| Earnings Per Share (EPS) | -1.25 |
Balance Sheet
The company has $52.23M in cash and $177.02M in debt, giving a net cash position of -$124.78M.
| Cash & Cash Equivalents | 52.23M |
| Total Debt | 177.02M |
| Net Cash | -124.78M |
| Retained Earnings | -1.49B |
| Total Assets | 189.48M |
| Working Capital | 123.26M |
Cash Flow
In the last 12 months, operating cash flow was -$92.72M and capital expenditures $0, giving a free cash flow of -$92.72M.
| Operating Cash Flow | -92.72M |
| Capital Expenditures | 0 |
| Free Cash Flow | -92.72M |
| FCF Per Share | -0.81 |
Margins
Gross margin is 96.62%, with operating and profit margins of -88.71% and -97.99%.
| Gross Margin | 96.62% |
| Operating Margin | -88.71% |
| Pretax Margin | -97.77% |
| Profit Margin | -97.99% |
| EBITDA Margin | -81.09% |
| EBIT Margin | -88.71% |
| FCF Margin | -63.49% |
Dividends & Yields
KPTI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -178.57% |
| FCF Yield | -105.03% |
Analyst Forecast
The average price target for KPTI is $5, which is 614.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 614.3% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -10.56 |
| Piotroski F-Score | 1 |